Dashboard
Manage Tickers

REGN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
11/06/2025 15:30:59

looking-into-regeneron-pharmaceuticals-incs-recent-short-interest
Looking Into Regeneron Pharmaceuticals Inc...
11/04/2025 19:00:36

michael-burry-is-super-bearish-on-palantir--with-5-million-puts
Michael Burry Is Super-Bearish On Palantir...
11/03/2025 23:17:30

Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, am...

rbc-capital-maintains-sector-perform-on-regeneron-pharmaceuticals-raises-price-target-to-708
RBC Capital Maintains Sector Perform on Re...
10/29/2025 16:56:39

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the pr...

wells-fargo-maintains-equal-weight-on-regeneron-pharmaceuticals-raises-price-target-to-615
Wells Fargo Maintains Equal-Weight on Rege...
10/29/2025 14:16:08

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price ...

cantor-fitzgerald-maintains-overweight-on-regeneron-pharmaceuticals-raises-price-target-to-740
Cantor Fitzgerald Maintains Overweight on ...
10/29/2025 13:50:33

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the pr...

guggenheim-maintains-buy-on-regeneron-pharmaceuticals-raises-price-target-to-865
Guggenheim Maintains Buy on Regeneron Phar...
10/29/2025 12:46:20

Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target fro...

b-of-a-securities-maintains-underperform-on-regeneron-pharmaceuticals-raises-price-target-to-627
B of A Securities Maintains Underperform o...
10/29/2025 12:06:41

B of A Securities analyst Tim Anderson maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Underperform and raises the ...

Core News & Articles
ModeX Therapeutics Enters License, Collabo...
10/29/2025 12:02:41

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collabora...

nasdaq-100-hits-26000-gold-falls-below-4000-whats-moving-markets-tuesday
Nasdaq 100 Hits 26,000, Gold Falls Below $...
10/28/2025 17:23:51

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech...

wayfair-qorvo-celestica-united-parcel-service-regeneron-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday
Wayfair, Qorvo, Celestica, United Parcel S...
10/28/2025 14:14:02

regenerons-q3-earnings-outperform-expectations-with-dupixent-strength-balancing-eylea-weakness
Regeneron's Q3 Earnings Outperform Expecta...
10/28/2025 13:13:27

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

regeneron-pharmaceuticals-q3-adj-eps-1183-beats-959-estimate-sales-3754b-beat-3585b-estimate
Regeneron Pharmaceuticals Q3 Adj. EPS $11....
10/28/2025 10:30:38

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $11.83 per share which beat the analyst consensus estima...

a-preview-of-regeneron-pharmaceuticalss-earnings
A Preview Of Regeneron Pharmaceuticals's E...
10/27/2025 15:01:00

heres-how-much-1000-invested-in-regeneron-pharmaceuticals-20-years-ago-would-be-worth-today
Here's How Much $1000 Invested In Regenero...
10/20/2025 16:14:58

fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times
FDA Unveils First Experimental Drugs Under...
10/17/2025 14:03:18

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

regenerons-libtayo-wins-positive-european-medicines-agency-opinion-for-high-risk-skin-cancer-treatment-after-surgery-and-radiation
Regeneron's Libtayo Wins Positive European...
10/17/2025 11:32:55

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency's (EMA) Committee for Medi...

Core News & Articles
FDA Awards First-Ever National Priority Vo...
10/16/2025 21:27:26

https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

eyepoint-pharmaceuticals-raises-capital-as-it-advances-lead-product-to-pivotal-study
EyePoint Pharmaceuticals Raises Capital As...
10/15/2025 15:01:34

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION